The FDA approved sirolimus 0.2% gel (Hyftor) as the first topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC), Nobelpharma announced. The approved indication ...

Hyftor 0.2% topical gel is supplied in 10 gram tubes containing 2mg of sirolimus per gram; it is available through a limited network of specialty pharmacies. Hyftor ™ (sirolimus topical gel) is now ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved topical Hyftor for the treatment of facial angiofibroma in patients who have tuberous sclerosis ...

Credit: FDA. The approval was based on data from a phase 3 trial that assessed Hyftor in 62 patients with facial angiofibroma associated with TSC. The Food and Drug Administration (FDA) has approved ...

This Angiofibroma Drugs market report work with respect to opportunities, challenges, drivers, market structures, and competitive landscape for the clients. The report is a complete overview of the ...

In a recent market intelligence analysis by Data Bridge Market Research, the Angiofibroma Drugs Market was thoroughly examined. The recently released report utilizes an attractive format to showcase ...

Juvenile angiofibroma (JA), a rare tumour developing in adolescent and young adult males, accounts for 0.05-0.5% of all head and neck tumours [1]. Juvenile angiofibroma is composed of histologically ...

Juvenile nasopharyngeal angiofibroma (JNA), a rare tumour developing in adolescent and young adult males, accounts for 0.05-0.5% of all head and neck tumours [1, 2]. Juvenile nasopharyngeal ...

A team of doctors at the Government Medical College and Hospital (GMCH) here diagnosed and treated a female patient for 'angiofibroma on the outer side of the nasopharynx', an ailment which is ...